TGRX-1942 Chinese Phase I for Advanced Solid Tumor And/or Relapsed/Refractory Hematologic Malignancies
Trial statusRecruiting
Trial phasePhase 1
Trial typeInterventional
Biological sexAll
Age18+
SponsorShenzhen TargetRx Co., Ltd.
About this trial
A phase I study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of TGRX-1942 in patients with advanced solid tumor and/or relapsed or refractory hematological malignancies
Eligibility criteria
Qualifiers
For dose escalation phase, patient is diagnosed with advanced/metastatic solid tumor who had failed standard therapies and does not have available effective treatment, or who relapsed from prior treatments
ECOG score of equals to or lower than 1
Life expectancy of at least 3 months
Adequate systemic and organ functions, including hematologic, hepatic and kidney functions
Disqualifiers
Allergic to any of the ingredient of the investigational drug
History of other primary malignancies
Have adverse/toxic effects from previous treatment that has not recovered to CTCAE 5.0 <= Grade 1
Received other anti-tumor treatments (i.e., chemotherapy, biologics, immunotherapy, targeted therapy, etc.) 28 days before first dose, or radiation therapy 14 days before first dose
Trial design
Treatments tested in this trial
- TGRX-1942
Treatment groups
90 Participants
are divided into 1 treatment groupSponsors and collaborators
Shenzhen TargetRx Co., Ltd.
Lead sponsor
Sir Run Run Shaw Hospital
Collaborator
Source ClinicalTrials.gov